AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KOCT 131 min read$CODX

Co-Diagnostics, Inc. (CODX): Entry into a Material Definitive Agreement

Co-Diagnostics, Inc. (CODX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Senior Secured Convertible Loan Transaction with J.J. Astor & Co. On October 9, 2026, Co-Diagnostics, Inc. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”) with J.J. Astor & Co. (the “Lender”), pursuant to

Original reporting
SEC EDGAR 8-K
Published Oct 13, 2026, 10:10 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 10:11 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$CODX
Bearish
high confidence
Mentioned
$CODX
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CODXBearishMed
01

Why it matters

The financing provides immediate liquidity but introduces conversion risk and high default interest, likely pressuring the share price in the short term.

02

Market read

First‑report disclosure of a material financing agreement for a micro‑cap biotech, modest trading relevance.

03

What to watch

The loan's conversion price floor and make‑whole provisions may limit dilution if the stock trades above the floor, mitigating downside.

Relevance 6/10Novelty 6/10Timing: today

Background

The filing details the terms of a senior secured convertible loan, including fees, conversion mechanics, and ATM waterfall distribution.

Company-level read

Ticker impact

$CODXBearishHigh confidence
Context

Co-Diagnostics filed an 8‑K reporting a senior secured convertible loan of up to $3.1 million, including an initial $2.1 million draw and convertible notes.

Expected impact

potential downside as conversion dilution and debt service pressure the share price

Evidence & confidence

New convertible loan creates future share issuance risk and a 19% default interest rate, which markets typically view as bearish for small‑cap equities.

Market effects

Sector

May signal increased financing activity in the diagnostics sector, but the small size limits broader impact.

Regional

Limited to US micro‑cap investors; no significant regional effect.

Global

Low; the deal is company‑specific and does not affect global markets.

Counterpoint

What could challenge this read

The cash infusion could fund growth initiatives that outweigh dilution concerns, offering upside potential.

Key entities

  • company
    Co-Diagnostics, Inc.

    Issuer of the convertible loan.

  • lender
    J.J. Astor & Co.

    Provider of the senior secured convertible loan.

Read at source← All news

Related articles

AUG 13
$CODXMed

Co-Diagnostics Reports Second Quarter 2026 Financial Results

Co-Diagnostics (Nasdaq: CODX) reported Q2 2026 results for the quarter ended June 30, 2026. Revenue was $0.17M vs $0.16M a year earlier. Operating loss was $6.2M, net loss $6.3M ($1.46/share). Cash was $3.6M. The company said it completed studies and submitted a 510(k) for its Flu A/B and RSV multiplex test, and raised $3.0M via private placement.

prnewswire.com6 min
AUG 13
$CODXMed

Co-Diagnostics Reports Second Quarter 2026 Financial Results

Co-Diagnostics, Inc. (CODX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Co-Diagnostics Reports Second Quarter 2026 Financial Results Advancing Commercialization Through FDA Submission, Global Clinical Progress and Manufacturing Expansion Strengthening Integrated Co-Dx PCR Platform Through Scientific Innovation, Cloud Connectivity and AI-

SEC EDGAR 8-K6 min
AUG 13
$CODXMed

Co-Diagnostics submits flu/RSV test after study of more than 1,400 patients

Co-Diagnostics (Nasdaq: CODX) reported Q2 2026 revenue of $0.17 million, up from $0.16 million a year earlier, with a net loss of $6.3 million ($1.46/share) versus a $7.7 million loss in Q2 2025. Cash fell to $3.6 million from $11.9 million. The company said it completed studies for an FDA 510(k) and CLIA waiver for its Flu A/B & RSV PCR test and raised $3.0 million in a private placement.

stocktitan.net6 min
AUG 6
$CODXMed

Co-Diagnostics Submits FDA 510(k) Premarket Notification for Upper Respiratory Point-of-Care Test

Co-Diagnostics (Nasdaq: CODX) said it submitted a Dual 510(k) premarket notification with a concurrent CLIA Waiver by Application to the FDA for its Co-Dx PCR Flu A/B & RSV upper respiratory multiplex test on the Co-Dx PCR Pro instrument. The filing follows clinical studies of 1,400 symptomatic patients and analytical work across 27 studies and 10,000+ PCR runs. If granted, the CLIA waiver would enable decentralized point-of-care use; the platform is not yet for sale.

prnewswire.com2 min
JUL 1
$CODXMed

EXCLUSIVE: Co-Diagnostics Reaches Regulatory Milestone for PCR Respiratory Test Platform - Co-Diagnostics

Co-Diagnostics (NASDAQ:CODX) said it completed clinical and analytical performance studies for its Co-Dx PCR Flu A/B & RSV multiplex test on the Co-Dx PCR Pro instrument. The company plans to include the results in its FDA submission package for a Dual 510(k) and CLIA Waiver by Application targeted for Q3 2026. Shares were down 0.65% premarket to $3.08.

benzinga.com4 min
MAY 29
$SPRCMedAI 8/10

Top Biotech Gainers: SPRC Deal Gets Nod, CODX Rallies, OTLK, AKTX, FTRE Drawing Investor Interest

SciSparc (SPRC) shares rose ~140% after its TSX Venture subsidiary received conditional approval to buy ~54% of private Israeli CliniQuantum for 56.6M NeuroThera shares (~$9.46M). Co-Diagnostics (CODX) gained ~53% for a third day amid Ebola PCR assay progress. Akari (AKTX) jumped ~38% on ASCO abstract acceptance and new KRAS-mutant synergy data; Outlook (OTLK) rose ~26% ahead of a June FDA resubmission.

rttnews.com6 min